Company Overview and News

8
Abattis Bioceuticals Provides Update on Vaporizer Product Line

2018-10-11 globenewswire
VANCOUVER, British Columbia, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce an update on our recent product line addition of three new vaporizers. Currently, the VB-1, VB-2, CA-2 and the KB-1 have now been made available for purchase through our website Abattis.com. Our vaporizers feature a 510 threaded battery that can be used with any third-party vaporizer cartridge.
ATTBF PM BATS 4162 ATT MO

 
Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil

2018-10-04 globenewswire
VANCOUVER, British Columbia, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE: ATT) (OTC: ATTBF) is pleased to announce that the research being done in conjunction with the University of British Columbia and Mitacs is close to completing their phase of testing. In Q1 2018, Abattis announced a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil.
ATTBF ATT

1
Abattis Unveils “Comfort”, Its Proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

2018-09-24 globenewswire - 1
VANCOUVER, British Columbia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes to launch Comfort on Cyber Monday through the Company’s wholly-owned subsidiary, Vergence Naturals Ltd.
ATTBF ATT

13
CBD Oil From Organic Hemp Wins Top Rating From Leading Marijuana Business Directory

2018-09-18 accesswire - 1
ASBURY PARK, NJ / ACCESSWIRE / September 18, 2018 / A pure CBD oil sourced from organic hemp has won a top rating from MarijuanaWerx, a leading marijuana business directory serving the cannabis business community in the United States and Canada, see here https://marijuanawerx.com/cbdpure/
STZ.B ATTBF ACBFF CHOOF RMHB STZ CGC LBUY CGRW ACB APH WEED APHQF CNAB ATT GWP

 
Abattis Strengthens Management Team and Provides Company Updates

2018-09-11 globenewswire
VANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates.
ATTBF ATT

6
Little Known CBG Could Rival CBD in Coming Years as the Next Big Thing in Cannabis

2018-09-04 accesswire - 1
ASBURY PARK, NJ / ACCESSWIRE / September 4, 2018 / There are over 100 cannabinoids in cannabis and hemp with THC and CBD being the better known among them. But a lesser known cannabinoid called CBG, or cannabigerol, is now attracting more and more attention for its' potential benefits, as more industry watchers suggest this cannabinoid may emerge as something significant that may even rival CBD oil in the coming years, see here https://marijuanawerx.
ATTBF ACBFF CHOOF RMHB CGC LBUY CGRW ACB APH WEED APHQF CNAB ATT GWP

 
Emerald Health Therapeutics Reports 2nd Quarter 2018 Financial Results and Provides Corporate Update

2018-08-30 globenewswire
VICTORIA, British Columbia, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the three and six months ended June 30, 2018. They are available for viewing on www.sedar.com or on the Company’s website. All figures are expressed in Canadian dollars unless otherwise stated.
ATTBF EMH TBQBF EMHTF ATT QBC

 
Abattis Prepares to Launch New Products Through Vergence Naturals

2018-08-28 globenewswire
VANCOUVER, British Columbia, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce that it plans to launch a new line of products designed to alleviate pain and inflammation through its wholly owned subsidiary, Vergence Naturals Ltd. (“Vergence”). The launch is anticipated to take place on Cyber Monday and the new product line will be the first of twelve products the Company hopes to launch over a 36-month period.
ATTBF ATT

96
Changing Marijuana Laws and CBD Sales Growth Fuels Active Domain Name Aftermarket

2018-08-24 accesswire - 2
ASBURY PARK, NJ / ACCESSWIRE / August 24, 2018 / The fast growing CBD markets in the U.S. and Canada, as well as the changing laws in the recreational and medical marijuana markets has spawned an active secondary market for domain name resellers of premium high-levels domain names for domains involving cannabis, marijuana, CBD, and CBG, see here https://marijuanawerx.com/.
ATTBF ACBFF CHOOF RMHB CGC LBUY CGRW TWMJF ACB APH WEED APHQF CNAB ATT GWP

 
Emerald Health Therapeutics Completes Acquisition of Licensed Dealer Northern Vine Canada

2018-08-15 globenewswire
VICTORIA, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) (Emerald) has completed the purchase of the remaining shares of Northern Vine Canada Inc. (Northern Vine) from Abattis Bioceuticals Corp. (Abattis) (CSE: ATT; OTC: ATTBF) for $2 million in cash and 1,093,938 common shares of Emerald (with a deemed value of $4 million, based on the trailing 30 day VWAP of Emerald shares as of July 19, 2018).
ATTBF EMH TBQBF EMHTF ATT

 
Abattis Announces Share Buy Back Program

2018-08-07 globenewswire
VANCOUVER, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it intends to proceed with a normal course issuer bid to purchase up to 20,986,909 of its common shares, representing 5% of its current issued and outstanding shares (the “Bid”). The Company is commencing the Bid because it believes that, from time to time, the market price of its common shares may not fully reflect the underlying value of the Company’s business and future prospects.
ATTBF ATT

 
Abattis Continues to Build on Recent Investments With Plans for Significant Revenue Growth

2018-07-31 globenewswire
VANCOUVER, British Columbia, July 31, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update as the Company moves to a phase of building on recent investments and anticipates significant revenue growth in the fourth quarter of 2018.
ATTBF EMH TBQBF EMHTF ATT

 
Abattis Completes Investment in XLABS Therapeutics to Launch New Cannabis Lab in Ontario

2018-07-24 globenewswire
VANCOUVER, British Columbia, July 24, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated June 28, 2018, it has closed its investment in XLABS Therapeutics (ONT) Inc. (“XLABS”).
ATTBF ATT

 
Abattis Enters Into Definitive Agreement to Sell Northern Vine Interest

2018-07-19 globenewswire
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) with Emerald Health Therapeutics, Inc. (“Emerald”) to dispose of (the “Disposition”) its 35% interest in Northern Vine Canada Inc. (“Northern Vine”) in exchange for $2 million in cash and $4 million in freely tradeable common shares of Emerald.
ATTBF EMH TBQBF EMHTF ATT

 
Emerald Health Therapeutics Completes Full Acquisition of Licensed Dealer Northern Vine to Advance Product Innovation

2018-07-19 globenewswire
VICTORIA, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (Emerald) has signed a definitive agreement (“Agreement”) to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) (CSE:ATT) (OTC:ATTBF), for $2 million in cash and $4 million in shares of Emerald stock. This transaction increases Emerald’s ownership of Northern Vine from 65% to 100%.
ATTBF EMH TBQBF EMHTF ATT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 00258G103